Clinical Trial Update: A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of the PARG inhibitor ETX-19477 in patients with advanced solid malignancies is currently recruiting, including breast cancer, ovarian cancer, e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Endometrial Cancer
• Gastric Cancer
• Ovarian Cancer
• Prostate Cancer

Drugs mentioned

• ETX-19477

Snippet

Sponsor: 858 Therapeutics, Inc. | Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING